Product Description
Mechanisms of Action: D2 Antagonist, 5-HT2A Antagonist, 5-HT1A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/03/2024 |
PubMed |
Cachd1 interacts with Wnt receptors and regulates neuronal asymmetry in the zebrafish brain. |
|
04/01/2024 |
PubMed |
How to tailor renorrhaphy technique during robot-assisted partial nephrectomy. |
|
04/01/2024 |
PubMed |
Urological surgery with the Hugo RAS™ System: insights into system adaptability. |